A5061211279- HIV Research and Treatment
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Viral Infections and Outbreaks Research
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- RNA Interference and Gene Delivery
- vaccines and immunoinformatics approaches
- Influenza Virus Research Studies
- HIV/AIDS drug development and treatment
- Hepatitis B Virus Studies
- Viral Infections and Vectors
- Herpesvirus Infections and Treatments
- Viral gastroenteritis research and epidemiology
- CRISPR and Genetic Engineering
- NF-κB Signaling Pathways
- CAR-T cell therapy research
- SARS-CoV-2 and COVID-19 Research
- Cytomegalovirus and herpesvirus research
- Immune Response and Inflammation
- Respiratory viral infections research
- T-cell and Retrovirus Studies
- Glycosylation and Glycoproteins Research
- Animal Disease Management and Epidemiology
National Institutes of Health
2012-2025
National Institute of Allergy and Infectious Diseases
2012-2025
OPKO Health (United States)
2022-2024
Sanofi (United States)
2013-2022
AVEO Oncology (United States)
2015-2021
Sanofi (France)
2016-2020
Breakthrough
2019
Ragon Institute of MGH, MIT and Harvard
2015
RAND Corporation
2014
Institut de Recherche Vaccinale
2003-2014
Cross-reactive neutralizing antibodies (NAbs) are found in the sera of many HIV-1-infected individuals, but virologic basis their neutralization remains poorly understood. We used knowledge HIV-1 envelope structure to develop antigenically resurfaced glycoproteins specific for structurally conserved site initial CD4 receptor binding. These probes were identify with NAbs CD4-binding (CD4bs) and isolate individual B cells from such an donor. By expressing immunoglobulin genes cells, we...
Designer Anti-HIV Developing a protective HIV vaccine remains top global health priority. One strategy to identify potential candidates is isolate broadly neutralizing antibodies from infected individuals and then attempt elicit the same antibody response through vaccination (see Perspective by Burton Weiss ). Wu et al. (p. 856 , published online 8 July) now report identification of three antibodies, isolated an HIV-1–infected individual, that exhibited great breadth potency neutralization...
Direct gene transfer offers the potential to introduce DNA encoding therapeutic proteins treat human disease. Previously, in humans has been achieved by a cell-mediated ex vivo approach which cells from blood or tissue of patients are genetically modified laboratory and subsequently returned patient. To determine feasibility safety directly transferring genes into humans, clinical study was performed. The foreign major histocompatibility complex protein, HLA-B7, introduced HLA-B7-negative...
Broadly neutralizing antibodies to HIV with similar specificities can be found in multiple HIV-infected individuals.
The nuclear factor kappaB (NF-kappaB) transcription is responsive to specific cytokines and stress often activated in association with cell damage growth arrest eukaryotes. NF-kappaB a heterodimeric protein, typically composed of 50- 65-kilodalton subunits the Rel family, which RelA(p65) stimulates diverse genes. Specific cyclin-dependent kinases (CDKs) were found regulate transcriptional activation by through interactions coactivator p300. domain interacted an amino-terminal region p300...
Public health measures have successfully identified and contained outbreaks of the severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), but concerns remain over possibility future recurrences. Finding a vaccine for this virus therefore remains high priority. Here, we show that DNA encoding spike (S) glycoprotein SARS-CoV induces T cell neutralizing antibody responses, as well protective immunity, in mouse model. Alternative forms S were analysed by immunization. These expression...
A recombinant β-galactosidase gene has been expressed in a specific arterial segment vivo by direct infection with murine amphotropic retroviral vector or DNA transfection the use of liposomes. Several cell types vessel wall were transduced, including endothelial and vascular smooth muscle cells. After infection, reporter was for at least 5 months, no helper virus detected. Recombinant expression achieved liposome-mediated limited to site absent from liver, lung, kidney, spleen. These...
A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested efficacy DNA prime-recombinant adenovirus 5 boost (DNA/rAd5) regimen in persons at increased risk HIV-1 United States.
The severe acute respiratory syndrome coronavirus (SARS-CoV) synthesizes several putative viral envelope proteins, including the spike (S), membrane (M), and small (E) glycoproteins. Although these proteins likely are essential for replication, their specific roles in SARS-CoV entry have not been defined. In this report, we show that S glycoprotein mediates through pH-dependent endocytosis. Further, define its cellular tropism demonstrate virus transmission occurs cell-mediated transfer by...
Vascular smooth muscle cell (SMC) proliferation in response to injury is an important etiologic factor vascular proliferative disorders such as atherosclerosis and restenosis after balloon angioplasty. The retinoblastoma gene product (Rb) present the unphosphorylated active form quiescent primary arterial SMCs, but rapidly inactivated by phosphorylation growth stimulation vitro. A replication-defective adenovirus encoding a nonphosphorylatable, constitutively of Rb was constructed. Infection...
A technique for the transfer of endothelial cells and expression recombinant genes in vivo could allow introduction proteins therapeutic value management cardiovascular diseases. Porcine expressing beta-galactosidase from a murine amphotropic retroviral vector were introduced with catheter into denuded iliofemoral arteries syngeneic animals. Arterial segments explanted 2 to 4 weeks later contained beta-galactosidase, an indication that they successfully implanted on vessel wall.